BIOTRON LIMITED — Investor Presentation 2010

Oct 19, 2010

==> picture [227 x 36] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

20 October 2010

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(8 pages by email)

Dear Madam

PRESENTATION TO INVESTORS

I attach a PowerPoint presentation as presented by Biotron Limited's CEO, Dr Michelle Miller, at the Australasian Life Science Investment Summit in Melbourne. The summit provides the opportunity to present to an international audience of investors and to showcase the best of Australia's biotechnology companies to the world.

About Biotron

Biotron Limited is engaged in the research, development and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on Hepatitis C virus (HCV) and HIV. The Company has BIT225 in clinical development for both HCV and HIV, and also has several earlier stage preclinical and research programs for other viral infections including Dengue, influenza and Hepatitis B.

For further information please contact Dr Michelle Miller, Managing Director, on (61-2) 9805 0488.

Yours sincerely

==> picture [105 x 67] intentionally omitted <==

Peter J. Nightingale Company Secretary

pjn5646

==> picture [721 x 68] intentionally omitted <==

==> picture [721 x 204] intentionally omitted <==

----- Start of picture text -----

ASX:BIT
----- End of picture text -----

Novel Small-Molecule Antiviral Drugs

Michelle Miller, CEO . . mmiller@biotron com au

==> picture [721 x 101] intentionally omitted <==

==> picture [721 x 68] intentionally omitted <==

• Established in 1999 as a s p in-out from the Australian National Universit y , Canberra; Based in Sydney, Australia

• IPO on ASX in Jan 2001 (Ticker code BIT)

• Focus on developing novel small molecule antiviral drugs

• Hep C, HIV, Dengue

• Key highlights

• Successful implementation of clinical trials for the Hep C and HIV programs

• • Successful capital raisings in challenging market conditions (A$2.7 m in 2010)

• E xper ence i d t eam, nc u i l di ng • Dr Michelle Miller (CEO) - Ex-J&J; Investment Manager with specialist bioscience fund manager

• Dr Carolyn Luscombe (Development Manager) – ex-Viridae and ViroMed

• • Dr Michael Hirshorn – Ex-Cochlear & ResMed; private equity fund manager

• • - Dr Denis Wade – Ex JJR; Director of Heartware

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

’
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

• Two clinical phase programs:

– Hepatitis C virus (BIT225) and HIV Clinical Trials Pro j ect Tar g et Discover y Preclinical Phase Ia Ph Ib Ph IIa Hep C p7 HIV Vpu Dengue M protein Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

Lead Product – BIT225
----- End of picture text -----

• BIT225 is a new investi ational oral dru in develo ment for treatin He C g g p g p

• infection

• Completed two clinical trials:

• Phase Ia – Placebo-Controlled, Randomized Study of the Safety and Pharmacokinetics of BIT225 in Healthy Volunteers (48 patient, single dose study); Status - completed

• Phase Ib - Placebo-Controlled, Randomized Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Patients (Males and F e m a l es) wi t h H epat i t i s C Vir us Inf ect i o n ( 1 8 pat i e n t, m u l t i p l e dose study); Status - completed in October 2009

• Phase IIa - Placebo-Controlled, Randomized Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Infection . Status - trial anticipated to complete by end 2010.

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

BIT225 Clinical Information
----- End of picture text -----

---

• First in class drug targeting p7 protein of Hep C virus

• p7 - Critical role in production of infectious Hep C virus in infected cells

• Proposed as new target for therapeutic intervention

• Phase Ia results indicated that BIT225 was well-tolerated at doses up to 600mg with no dose-limiting toxicities

• Phase Ib results indicated that

• 200 mg BIT225 significantly reduced virus levels compared to placebo (p=0.0002)

• On an individual level, 3 of the 6 subjects receiving 200 mg of BIT225 had significant reductions in viral loads.

• Results were first indication that a p7-inhibitor has therapeutic potential

• Phase IIa – 24 subjects (Hep C+, genotype 1) commencing standard of care (SOC) will receive 200 or 400 mg BIT225 (or placebo) twice daily for first 28 days of SOC.

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

==> picture [721 x 68] intentionally omitted <==

• Hep C worldwide market ~US$2.8 billion; predicted to expand to >US$10 billion

• Over 170 million individuals infected causing severe liver disease, including cirrhosis and hepatocellular carcinoma

• L ow response rate ue to comp d li ance ssues w t i i h SOC as we ll as preva ence o l f interferon-resistant, genotype 1 virus;

• Documented need for new specific antiviral drugs for Hep C

• Potential to combine BIT225 with current approved or next generation Hep C drugs (synergistic with both in vitro )

• BIT225 is first-in-class

• Biotron has back-up drugs and proprietary assays to facilitate development of 2[nd] generation drugs

• Strong patent protection – 5 patent families filed worldwide

• Cu rr e n t l y u n pa r t n e r ed; see kin g su i tab l e pa r t n e r a f te r Ph ase II a t ri a l

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

==> picture [721 x 68] intentionally omitted <==

----- Start of picture text -----

Ca ital Structure
p
----- End of picture text -----

==> picture [721 x 69] intentionally omitted <==

Shares on issue 121.8 m

Listed options 108 m

Unlisted options 6.4 m Cash at 30 June10 A$1.78 m

Current market cap A$12 . 8 m

Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au

Biotron Limited